Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | TK2 | O00142 | 9/20 | 0.57 |
| ▸ | NT5C | Q8TCD5 | 1/20 | 0.40 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921134 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2919193 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2921132 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2919190 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2915110 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2915125 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2919241 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2915114 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2915121 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2920844 | 0.91 | TK1 (0.53) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1204415-B1 | 5-(E)-BROMOVINYL URACIL ANALOGUES AND RELATED PYRIMIDINE NUCLEOSIDES AS ANTI-VIRAL AGENTS AND METHODS OF USE | UNIV YALE (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20040053891-A1 | 5-(E)-bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-18 | — | — | US | disclosed |
| US-6653318-B1 | Varicella zoster and epstein barr viruses | YALE UNIVERSITY | 2003-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053891-A1 | 5-(E)-bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use | TYMP, DPYD, CXCL8 | TK1 19/4885CYP1A2 3291/4885CYP3A4 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.